Time-to-event analysis with treatment arm selection at interim

被引:15
作者
Di Scala, L. [1 ]
Glimm, E. [1 ]
机构
[1] Novartis Pharma AG, Basel, Switzerland
关键词
adaptive design; Bayesian statistics; oncology; treatment selection; CLINICAL-TRIALS; DESIGNS;
D O I
10.1002/sim.4342
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This paper discusses the application of an adaptive design for treatment arm selection in an oncology trial, with survival as the primary endpoint and disease progression as a key secondary endpoint. We carried out treatment arm selection at an interim analysis by using Bayesian predictive power combining evidence from the two endpoints. At the final analysis, we carried out a frequentist statistical test of efficacy on the survival endpoint. We investigated several approaches (Bonferroni approach, 'Dunnett-like' approach, a conditional error function approach and a combination p-value approach) with respect to their power and the precise conditions under which type I error control is attained. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:3067 / 3081
页数:15
相关论文
共 26 条
[1]  
[Anonymous], 2021, Bayesian data analysis
[2]  
[Anonymous], 1980, Multivariate Analysis
[3]   Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [J].
Barnes, Peter J. ;
Pocock, Stuart J. ;
Magnussen, Helgo ;
Iqbal, Amir ;
Kramer, Benjamin ;
Higgins, Mark ;
Lawrence, David .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2010, 23 (03) :165-171
[4]  
Bauer P, 2004, Stat Med, V23, P1333, DOI 10.1002/sim.1759
[5]  
Bernardo J. M., 2009, BAYESIAN THEORY, V405
[6]   Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology [J].
Brannath, Werner ;
Zuber, Emmanuel ;
Branson, Michael ;
Bretz, Frank ;
Gallo, Paul ;
Posch, Martin ;
Racine-Poon, Amy .
STATISTICS IN MEDICINE, 2009, 28 (10) :1445-1463
[7]  
Cytel Inc, 2007, E 5 0 MAN
[8]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[9]  
FDA, 2010, UCM201790 FDA
[10]  
FDA, 2007, UCM071590 FDA